Kyverna Therapeutics (KYTX)

• Market cap: $474M
• 1 day: 23.23%
• 5 days: 31.63%
• 1 month: 51.12%
• 3 months: 176.73%
• 6 months: 243.49%
• Year to date: 176.02%
• 1 year: 155.19%
• 5 years: -63.93%
• 10 years: -63.93%
• Sector: Healthcare
• Industry: Biotechnology

About: Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Employees: 129